EP0674514A1 - Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle - Google Patents

Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle

Info

Publication number
EP0674514A1
EP0674514A1 EP94902735A EP94902735A EP0674514A1 EP 0674514 A1 EP0674514 A1 EP 0674514A1 EP 94902735 A EP94902735 A EP 94902735A EP 94902735 A EP94902735 A EP 94902735A EP 0674514 A1 EP0674514 A1 EP 0674514A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
piperidine
ethyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94902735A
Other languages
German (de)
English (en)
Inventor
Thomas Henry Brown
David Gywn Smithkline Beecham Pharmac. Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0674514A1 publication Critical patent/EP0674514A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to cyclic secondary amine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
  • the present invention therefore provides, in a first aspect, the use of a compound of formula (I):
  • W is -(CH 2 ) 4 , (CH 2 ) 5 , -(CH 2 ) 2 O(CH 2 )2 or -(CH 2 ) 2 S(CH 2 ) 2 n is 0 to 6; is 0 to 3;
  • R 1 is hydrogen, Cj.galkyl or phenylC ⁇ _4alkyl
  • Ar is aryl or heteroaryl, each of which may be optionally substituted; or a pharmaceutically acceptable salt thereof as a therapeutic agent.
  • W preferably represents (CH 2 )4 or (CH 2 )5
  • the group -(CH 2 ) n A(CH 2 ) m Ar may be substituted on any carbon atom in the ring.
  • W is (CH 2 )4 or (CH 2 )5 the substituent is preferably ⁇ to the ring nitrogen atom.
  • n, m and A should be chosen such that the chain (CH 2 ) n A(CH 2 ) m contains at least one atom.
  • the length of the chain -(CH 2 ) n A(CH 2 ) m is from 2 to 6 atoms.
  • Preferred values for n and m depend on the group A.
  • A is oxygen the sum of n+m is from 1 to 5; for example n may be 1 or 2 and m may be zero.
  • A is preferably oxygen or a bond.
  • suitable groups include, for example, unsaturated monocyclic and unsaturated or partially saturated bicyclic and tricyclic ring systems of up to 15 carbon atoms, such as, for example, phenyl, naphthyl, tetrahydronaphthyl, fluorene, fluorenone, dibenzosuberene and dibenzosuberenone. Preferred are optionally substituted phenyl rings.
  • An aryl group may be substituted, for example, by a C ⁇ _ alkylenedioxy group (e.g. phenyl substituted by a 3,4-methylenedioxy group) or by 1 to 3 substituents selected from halogen, C j ⁇ alkoxy, nitro, SC ⁇ _ alkyl, NR 2a R 2b (in which R 2a and R 2b independently represent H or C ⁇ _4alkyl), OCF3, Cj.galkyl, trifluoromethyl, CN, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted benzoyl, optionally substituted phenylC ⁇ _4alkyl and optionally substituted phenylC 1 _4alkoxy .
  • a C ⁇ _ alkylenedioxy group e.g. phenyl substituted by a 3,4-methylenedioxy group
  • substituents selected from halogen, C j ⁇ alkoxy, nitro, SC ⁇ _ alky
  • Suitable optionally substituted phenylCj_4alkyl groups include, for example benzyl.
  • Suitable optionally substituted phenylC ⁇ _4alkoxy groups include, for example benzyloxy groups.
  • Suitable substituents for said optionally substituted phenyl, phenoxy, benzoyl, phenylC ⁇ _4alkyl and phenylC ⁇ alkoxy groups include for example halogen, Cj ⁇ alkyl, C ⁇ alkoxy, nitro and trifluoromethyl groups.
  • the aryl group is a phenyl ring substituted by one or two substituents, in particular, by a phenyl, phenyl(Cj_4)alkyl, phenoxy, benzoyl or phenylC ⁇ _4alkoxy group; or by two chloro atoms especially in the 3- and 4-positions of the phenyl ring.
  • suitable groups include, for example, unsaturated or partially saturated bicyclic and tricyclic ring systems containing at least one heteroatom.
  • a bicyclic ring system preferably contains 8 to 10 ring members, such as quinolinyl and tetrahydroquinolinyl.
  • a tricyclic ring system preferably contains from 11 to 14 ring members, and most preferably has the structure :
  • Y 1 represents Y(CH 2 ) r
  • Y is O, S or NR ⁇ (where R ⁇ is hydrogen or Cj_4alkyl)
  • q is 0, 1 or 2
  • r is 0 or 1, or is a corresponding dehydro ring system.
  • tricyclic heteroaryl groups include dibenzofuranyl, dibenzothienyl, carbazole, N-methylcarbazole, acridine and dibenzoxepine.
  • the heteroaryl ring can be linked to the remainder of formula (I) via any suitable ring atom.
  • Suitable substituents for said heteroaryl rings include, for example, 1 to 3 substituents selected from halogen, trifluoromethyl, C ⁇ 4alkyl and C ⁇ 4alkoxy.
  • Alkyl groups present in the compounds of formula (I), alone or as part of another group, can be straight or branched.
  • a C ⁇ galkyl group may be for example methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or any branched isomer thereof such as iso ⁇ propyl, tert-butyl or _yec-pentyl.
  • Particularly preferred compounds of formula (I) for use according to the present invention are those wherein W is (CH 2 )5, the substituent -(CH ) n A(CH 2 ) m Ar is ⁇ to the ring nitrogen atom, A is oxygen, n is 1 or 2, m is zero and Ar is phenyl substituted by one of benzyl, benzoyl, phenoxy or benzyloxy, or by two chloro atoms, or Ar is dibenzofuranyl. It will be appreciated that for use in medicine a salt of a compound (I) should be pharmaceutically acceptable.
  • Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, methanesulphonate or similar pharmaceutically acceptable inorganic or organic acid addition salts.
  • Other non- pharmaceutically acceptable salts, such as oxalates, may be used for example in the isolation of final products and are included within the scope of this invention.
  • Ar represents phenyl substituted by benzoyl
  • a particularly preferred group of compounds wherein Ar represents benzoylphenyl is that in which W is (CH 2 )5, A is oxygen, n is 1 or 2 and m is zero. Most preferably the substituent -(CH 2 ) n A(CH 2 ) m Ar is ⁇ to the ring nitrogen atom.
  • Particular compounds for use according to the invention include: 2-[2-(4-benzyloxyphenoxy)ethyl]piperidine, 2- [2-(4-phenoxyphenoxy)ethyl]piperidine, 2-[2-(2-benzylphenoxy)ethyl]piperidine, 4-f2-(3,4-dichlorophenoxy)ethyl]piperidine, 4-f2-(4-benzyloxyphenoxy)ethyl]piperidine, 4-f2-(4-benzylphenoxy)ethyl]piperidine, 3-(4-benzyloxyphenoxymethyl)piperidine, 3-(4-benzylphenoxymethyl)piperidine, 2-[4-benzylphenoxymethyl]piperidine, 2-[4-benzyloxyphenoxymethyl]piperidine, (S)-2-[4-benzylphenoxymethyl]pyrrolidine, 2-[2-(3-benzoylphenoxy)ethyl]piperidine, 2- [2- (4- benzoylphenoxy)e
  • Other preferred compounds for use according to the present invention include : 2-f2-(2-dibenzofuranyloxy)ethyl]piperidine, 2-[2-(3,4-dichlorophenoxy)ethyl]piperidine, 2-[2-(4-benzylphenoxy)ethyl]piperidine, and salts thereof.
  • a compound of formula (I) may be prepared by a process which comprises:
  • R ⁇ a is hydrogen or an N-protecting group, and W, n, m, and Ar are as described above.
  • the present invention also provides a process for preparing a novel compound of formula (I) e.g a compound of formula (I) wherein W is -(CH 2 )4 and the group -(CH 2 ) n A(CH ) m Ar is ⁇ to the pyrrolidine nitrogen atom, or a compound as specifically named above, which process comprises any of processes (a) to (g) described above,as approporiate, followed where necessary by removal of the N-protecting group R4, and optionally thereafter forming a salt.
  • processes (a) to (g) described above,as approporiate, followed where necessary by removal of the N-protecting group R4, and optionally thereafter forming a salt Those skilled in the an will readily be able to determine which specific processes will be applicable to the preparation of a given compound.
  • reaction between a compound of formula (II) and a compound L(CH 2 ) m Ar can take place under conditions which depend on the nature of the group L and the value of m.
  • L is halogen or a sulphonic acid residue such as a tosylate or mesylate and m is other than zero
  • the reaction is carried out under standard conditions in a solvent, optionally in the presence of a base.
  • a fluoro-substituted aryl compound F-Ar is employed in process (a) (to prepare compounds where m is zero)
  • the reaction is effected in the presence of a strong base such as sodium hydride, and in an inert organic solvent such as DMSO or dimethylformamide.
  • reaction between a compound of formula (IH) and a compound of formula HA (CH 2 ) m Ar can take place under conditions which depend on the nature of L and A.
  • L 1 is hydroxy
  • m is 0
  • a 1 is oxygen or sulphur
  • the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine.
  • the leaving group L may be for example a halogen atom or a sulphonyloxy group eg. methane-sulphonyloxy or p-toluene sulphonyloxy.
  • the reaction may be effected in the presence or absence of solvent and at temperature in the range 0 to 200°C.
  • a compound of formula (IV) can be effected by methods known in the art, for example using a reducing agent such as lithium aluminium hydride.
  • a compound of formula (IV) can be prepared (for example as described below) and reduced in a 'one-pot' reaction, without isolation of compound (IV) itself.
  • reaction between a compound of formula (V) and a compound of formula X 1 Ar in process (d) can take place under standard conditions known to those skilled in the an for the formation of carbon-carbon bonds.
  • Reduction of a compound of formula (VI) according to process (e) may be effected for example by hydrogenation, using a noble metal catalyst such as platinum, palladium or platinum oxide, suitably in a solvent such as an alcohol eg. ethanol.
  • a noble metal catalyst such as platinum, palladium or platinum oxide
  • Process (f) may be effected using a Wadsworth-Emmons reagent of the formula Ar(CH 2 ) m +lP(O)(OAlk) 2 , such as a diethylphosphonate, or a Wittig reagent of the formula Ar(CH 2 ) m+ ⁇ PPh3X" (where X" is an anion) which compounds are available commercially or can be prepared by known methods.
  • the reaction may be carried out in a solvent such as tetrahydrofuran optionally containing a crown ether such as 15-crown-5 or 18-crown-6, and in the presence of a strong base such as sodium hydride, or potassium tert-butoxide.
  • Interconversion reactions according to process (g) may be effected by methods well known in the art.
  • Protecting groups R ⁇ include lower alkyl groups such as methyl; aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl; and acyl groups such as acetyl, trifluoroacetyl, benzoyl, methoxycarbonyl, ethoxycarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl.
  • a protecting group R ⁇ a is preferably alkyl e.g. methyl or aralkyl e.g. benzyl. Such groups may be removed by methods which are well known in the art.
  • alkyl group such as methyl may be removed by treatment with a haloalkyl haloformate such a 1-chloromethylchloroformate, aralkyl group such as benzyl may be cleaved by hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis.
  • a protecting group R ⁇ or R ⁇ a present in any of the above compounds (II) to (VII) as well as compounds (VIII) below should be chosen such that it will not be cleaved by or participate in any of the reactions that the particular compound is intended to undergo, and furthermore such that its removal will not disturb any other groups or moieties present in the molecule. Such factors can be readily ascertained by those skilled in the art, to whom appropriate protecting groups will thus be readily apparent.
  • acyl group may be introduced by reaction with an appropriate acid derivative such as an acid chloride or anhydride, or an activated ester, e.g. an alkyldicarbonate such as di-tert- butyldicarbonate or a haloformate such as ethylchloroformate.
  • an appropriate acid derivative such as an acid chloride or anhydride
  • an activated ester e.g. an alkyldicarbonate such as di-tert- butyldicarbonate or a haloformate such as ethylchloroformate.
  • the compounds of formula (II) in which A 1 is oxygen can be prepared by reduction of a compound of formula (VIII):
  • R ⁇ should be a group such as alkyl, which is not cleaved by reductive conditions.
  • Compounds of formula (HI) wherein L 1 is OH can be prepared as described for compounds of formula (II), and compounds of formula (HI) wherein L 1 is a halogen atom, or a mesyloxy or tosyloxy group can be prepared from the corresponding alcohol in conventional manner.
  • -(CH 2 ) n _ ⁇ C(O)N(R 1 )(CH ) m Ar may be prepared for example by reaction of a corresponding compound wherein R 5 represents -(CH 2 ) n _ ⁇ CO 2 H or an activated derivative thereof such as an acid halide, ester or anhydride, with an amine of formula
  • a compound of formula (VI) may be prepared using the general methods described in processes (a) to (d) above.
  • Compounds of formula (VII) may be prepared by conventional methods, for example the oxidation of a compound of formula (II) wherein A 1 is oxygen, or conversion of the corresponding ester, e.g. by reaction with thionyl chloride and
  • N,O-dimethylhydroxylamine hydrochloride to give the N-methyl-N-methoxy- carboxamide, which can be reduced to the aldehyde using diisobutylaluminium hydride.
  • Compounds of formula (VII) wherein n is 1 may be prepared from the corresponding compound wherein n is zero by various methods. For example the aldehyde wherein n is zero may be treated with (methoxymethyl) triphenylphosphonium chloride and potassium t-butoxide, followed by a strong acid, e.g. concentrated sulphuric acid, resulting in the aldehyde wherein n is 1.
  • aldehyde may be converted to the conesponding cyanomethyl derivative as described in EPA 363085 followed by acid hydrolysis, conversion to the N-methyl-N-methoxycarboxamide and reduction. These procedures may also be used to form higher homologues.
  • a compound of formula (I) When a compound of formula (I) is obtained as a mixture of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
  • Suitable resolving agents include optically active acids such as R-(-)- or S-(+)-mandelic acid.
  • Compounds of formula (I) have been found to exhibit calcium influx blocking activity for example in neurons. As such the compounds are expected to be of use in therapy in treating conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans.
  • the compounds are expected to be of use in the treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders; mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal.
  • ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders; mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal.
  • the invention therefore provides the use of a compound of formula (I) in the manufacture of a medicament for the treatment of disorders where a calcium channel antagonist is indicated.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof may be used in the manufacture of a medicament for the treatment of a condition or disease related to (e.g. caused or exacerbated by) the accumulation of calcium in the brain cells of a mammal e.g a human, such as for example, any of the aforementioned conditions.
  • the present invention provides a method of treatment of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the compounds of the present invention are usually administered in a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • the compounds of the invention may be administered by any convenient method for example by oral, parenteral, buccal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
  • the compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water • with a suspending agent, preservative, flavouring or colouring agent.
  • a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water • with a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • Both liquid and solid compositions may contain other excipients known in the pharmaceutical art, such as a cyclodextrin or a solubilising agent such as Cremophor.
  • composition is in unit dose form such as a tablet, capsule or ampoule.
  • Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 400mg per day.
  • the total daily dosage by oral administration will be in the range 1 to 2000 mg and the total daily dosage by parenteral administration will be in the range 0.1 to 400 mg.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more.
  • Ca 2+ current was measured in vitro using cell preparations of sensory neurons from dorsal root ganglia as described in WO92/02501 and WO92/02502.
  • Buffer to pH ca 7 Solvent/complexing agent to 100 ml Buffer : Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.
  • Solvent Typically water but may also include cyclodextrins (1-100 mg) and co-solvents such as propylene glycol, polyethylene glycol and alcohol.
  • Diluent e.g. Microcrystalline cellulose, lactose, starch Binder : e.g. Polyvinylpyrrolidone, hydroxypropymethylcellulose
  • Disintegrant e.g. Sodium starch glycollate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate.
  • Suspending agent e.g. Xanthan gum, microcyrstralline cellulose
  • Diluent e.g. sorbitol solution, typically water
  • Preservative e.g. sodium benzoate
  • Buffer e.g. citrate
  • Co-solvent e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin
  • Example la The product of Example la (6.0g, 16.03 mmole) was dissolved in glacial acetic acid/hydrogen bromide (20ml, 45w/v, excess). The solution was stood at room temperature for two hours and heated on a steam-bath for three hours. The material was then cooled, poured onto water and the aqueous phase basified with 50% NaOH. The mixture was extracted with dichloromethane (X2) and the combined organic extracts washed (water, brine), dried (MgSO4) and evaporated to give an oil (4.44g). This material was purified by flash chromatography on silica gel.
  • Example 2a The product of Example 2a (6.0g, 16mM) was dissolved in dichloromethane (80ml) and stirred at room temperature under nitrogen. A solution of trifluoroacetic acid (7.5ml) in dichloromethane (20ml) was added dropwise over 10 minutes and the colourless solution stirred for a further 2 hours. The mixture was evaporated and 2N. NaOH (100ml) added to the oily residue to produce a white, oily solid. This was extracted with dichloromethane (X2) and the combined organic extracts washed (H O, brine), dried (Na 2 SO4) and evaporated to dryness to leave a colourless oil (3.53g).
  • Example 2a Replacing the product of Example 2a with the product of Example 8a (4.5g, 0.011 mole) in the method of Example 2 and using the corresponding molar proportions of the other reagents gave the title compound as the free base.
  • This material was dissolved in ethyl acetate and excess ethereal HCl added. A white solid precipitated which was collected , and recrystallised from ethyl actetate to give the title compound as white needles (2.14g), M.P.
  • Example 12a 2-[4-Benzylphenoxymethyl]piperidine hydrochloride
  • the product of Example 12a 0.5g was converted to free base (equilibration between N. NaOH and CH 2 C1 2 - organic layer dried, washed and evaporated), producing a colourless oil which was dissolved in toluene (10ml).
  • To the stirred solution at room temperature under argon was added dropwise a solution of 1-chloromethyl chloroformate (0.28g, excess) in dry toluene (5ml). The mixture was heated at reflux temperature for 4 hours, concentrated almost to dryness, methanol (20ml) added and die mixture heated again at reflux temperature for 2 hours. The solvent was evaporated off to produce an oil which solidified on standing.
  • Example 3 The product of Example 3 was converted to free base in d e usual way (equilibration between N. NaOH and CH 2 C1 2 ) to produce an oil (1.75g, 5.92mM). This oil was dissolved in ethyl acetate (15ml) and S-(+)-mandelic acid (0.9g, 5.92mM) in etiiyl acetate (15ml) added. On refrigeration crystals separated and were collected (2.31 g). This material was crystallised five times from ethyl acetate/methanol (monitored by chiral HPLC) to give a white solid (0.83g). Conversion to free base in the usual way gave an oil (0.56g).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Utilisation d'un composé de formule (I), ou d'un sel pharmaceutiquement acceptable de ce dernier comme agent thérapeutique. Certains nouveaux composés de formule (I) et des procédés de préparation desdits composés sont également décrits. Dans la formule (I), W représente -(CH2)4, (CH2)5, -(CH2)2O(CH2)2 ou -(CH2)2S(CH2)2; n représente un entier compris entre 0 et 6; m représente un entier compris entre 0 et 3; A représente une liaison, -CH=CH-, -C=C, oxygène, soufre ou NR1; R1 représente hydrogène, C¿1-8? alkyle ou phényle C1-4 alkyle; et Ar représente aryle ou hétéroaryle qui peuvent chacun être facultativement substitués.
EP94902735A 1992-12-15 1993-12-07 Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle Withdrawn EP0674514A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929226111A GB9226111D0 (en) 1992-12-15 1992-12-15 Madicaments
GB9226111 1992-12-15
PCT/EP1993/003473 WO1994013291A1 (fr) 1992-12-15 1993-12-07 Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle

Publications (1)

Publication Number Publication Date
EP0674514A1 true EP0674514A1 (fr) 1995-10-04

Family

ID=10726633

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94902735A Withdrawn EP0674514A1 (fr) 1992-12-15 1993-12-07 Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle

Country Status (8)

Country Link
EP (1) EP0674514A1 (fr)
JP (1) JPH08504419A (fr)
CN (1) CN1091636A (fr)
AU (1) AU5698394A (fr)
GB (1) GB9226111D0 (fr)
MX (1) MX9307946A (fr)
WO (1) WO1994013291A1 (fr)
ZA (1) ZA939317B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
GB9411052D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Medicaments
WO1996002494A1 (fr) * 1994-07-14 1996-02-01 Smithkline Beecham Plc Derives de benzocycloalcoylamine utiles comme antagonistes du canal a calcium
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
AU713236B2 (en) * 1996-02-15 1999-11-25 Sankyo Company Limited Diarly alkane derivatives containing an alicyclic group, their preparation and their theraputic and prophylactic uses
US6110937A (en) 1997-04-03 2000-08-29 Syntex Usa, Inc. Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain
CA2232147A1 (fr) * 1997-04-03 1998-10-03 F. Hoffmann-La Roche Ag Derives de la phenoxymethylpiperidine
US6251919B1 (en) 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) * 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
AU2398001A (en) * 1999-12-21 2001-07-03 Mitsubishi Pharma Corporation Remedies and/or preventives for nervous system disorders
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
EP1318988A2 (fr) 2000-09-11 2003-06-18 Sepracor, Inc. Ligands pour les recepteurs de monoamine et transporteurs, et procedes d'utilisation de ces derniers (neurotransmission)
BRPI0408136A (pt) 2003-03-07 2006-03-01 Astellas Pharma Inc derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
EP1735302B1 (fr) 2004-02-27 2010-06-16 Eli Lilly And Company Derives de 4-amino-piperidine utilises en tant qu'inhibiteurs de l'absorption des monoamines
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
NZ566788A (en) 2005-09-21 2012-10-26 Decode Genetics Ehf Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
US7576102B2 (en) * 2005-12-21 2009-08-18 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
CN107846898B (zh) 2015-05-01 2023-07-14 佐治亚州立大学研究基金会 用于管理低氧诱导因子相关病症的二苯基甲醇衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3360526A (en) * 1964-01-15 1967-12-26 Bristol Myers Co Heterocyclicamino methylene ethers of benzylphenols
GB1096441A (en) * 1964-01-15 1967-12-29 Bristol Myers Co Ethers of benzyl phenols and a process for the preparation thereof
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
GB1319252A (en) * 1969-06-05 1973-06-06 Ciba Geigy Ag 1-phenyl-alkanols and process for making same
DE2728898A1 (de) * 1977-06-27 1979-01-18 Thomae Gmbh Dr K Neue morpholinderivate
DE2811952A1 (de) * 1978-03-18 1979-10-31 Merck Patent Gmbh Phenoxyalkylamine und verfahren zu ihrer herstellung
FR2443246A1 (fr) * 1978-12-05 1980-07-04 Pharmindustrie Nouveaux medicaments a base de derives de la phenyl-1 (piperidyl-4)-3 propanone-1
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US4822778A (en) * 1988-01-19 1989-04-18 Gunnar Aberg Membrane stabilizing phenoxy-piperidine compounds and pharmaceutical compositions employing such compounds
US5169855A (en) * 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
MX9100513A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
MX9100517A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
WO1993015052A1 (fr) * 1992-01-28 1993-08-05 Smithkline Beecham Plc Composes utilises comme antagonistes des canaux calciques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9413291A1 *

Also Published As

Publication number Publication date
GB9226111D0 (en) 1993-02-10
CN1091636A (zh) 1994-09-07
ZA939317B (en) 1995-06-13
JPH08504419A (ja) 1996-05-14
MX9307946A (es) 1994-08-31
WO1994013291A1 (fr) 1994-06-23
AU5698394A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
EP0674514A1 (fr) Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle
US6610711B2 (en) 4-phenylpiperidines for the treatment of pruritic dermatoses
AU8327191A (en) N-hydrocarbyl-4-substituted piperidines, their preparation and use as calcium blocking agents
JP2003515588A (ja) アルフェンタニル、スフェンタニルおよびレミフェンタニルの新合成法
EP0629190A1 (fr) Composes utilises comme antagonistes des canaux calciques
AU649468B2 (en) 3-substituted piperidine derivatives
KR100694682B1 (ko) 4-치환 피페리딘 유도체 불화물
JP2000086603A (ja) 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体
CZ210694A3 (en) Derivatives of piperidine, their use for preparing pharmaceutical preparations, process of their preparation, intermediates for preparing thereof and pharmaceutical compositions based thereon
WO1992022527A2 (fr) Derives de pyrrolidine 3-substitues comme antagonistes du calcium
JPH06500076A (ja) ピペリジン化合物、その合成およびその使用方法
RU2418794C2 (ru) ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА И БЕНЗО[h]ИЗОХИНОЛИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГИСТАМИНА H3
IE922090A1 (en) 2-(1-piperidyl)ethanol derivatives, their preparation and¹their therapeutic application
EP0763022A1 (fr) Piperidines, pyrrolidines, morpholines et thiomorpholines a substitution phenoxyalcoyle, en tant qu'antagonistes des canaux a calciques
AU705427B2 (en) Alpha-(substituted alkylphenyl) -4-(hydroxydiphenylmethyl)-1-piperidine butanol derivatives, their preparation and their use as anti-histamines, anti-allergy agents and bronchodilators
KR20010051474A (ko) 4-히드록시-4-페닐피페리딘 유도체 및 이를 함유하는 의약
JPH07503462A (ja) カルシウムチャンネル拮抗薬としてのアザビシクロ化合物
WO1995024390A1 (fr) Nouvelles piperidines substituees par phenyl(-alkyl/alkoxy)-1-aminoalkyle et pyrolidines utilisees comme antagonistes des canaux calciques
NZ528839A (en) Antihistaminic piperidine derivatives and intermediates
JPH09504014A (ja) カルシウムチャネル拮抗薬としてのアミン誘導体類
EP0125315A1 (fr) Derives de phenoxyaminopropanol
EP0763021A1 (fr) Piperidines, pyrrolidines, morpholines et tiopmorpholines a substitution phenoxyalcoyle en tant qu'antagonistes des canaux calciques
KR910000034B1 (ko) 하이드로피리딘 유도체의 제조방법
JP2000319258A (ja) ４−置換ピペリジン誘導体フッ化物
JPH08208595A (ja) スルホンアミド化合物、その製造法および剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 19980105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980516